HCW Biologics highlights TGF-β trap and IL-15 fusion immunotherapy approach
HCW Biologics says its TGF-β trap and IL-15 fusion platform is a novel moiety intended to enhance immunotherapeutic activity against diseased cells.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.